2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.75 USD
+0.19 (4.17%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
2seventy bio, Inc. (TSVT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.20 | $25.00 | $2.00 | 145.61% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for 2seventy bio, Inc. comes to $11.20. The forecasts range from a low of $2.00 to a high of $25.00. The average price target represents an increase of 145.61% from the last closing price of $4.56.
Analyst Price Targets (5 )
Broker Rating
2seventy bio, Inc. currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TSVT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 4 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 2.43 | 2.43 | 2.43 | 2.50 | 2.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Guggenheim Securities | Kelsey Goodwin | Hold | Hold |
6/6/2024 | Goldman Sachs | Salveen Richter | Hold | Strong Sell |
5/9/2024 | Canaccord Genuity | John L Newman | Not Available | Strong Buy |
4/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Hold | Hold |
1/31/2024 | SVB Securities | Daina M Graybosch | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $11.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 0.01 |